GHRP-2 research and evidence overview

GHRP-2 sits in an unusual position. Its ability to trigger growth hormone release is not in question — it is reliable enough that clinicians use a single injection as a diagnostic stimulus to test whether a patient's pituitary can produce GH. What is missing is any published trial testing whether repeated GHRP-2 dosing produces a benefit: no body composition study, no strength study, no long-term safety data. The best-documented human effect other than the GH spike is a substantial increase in food intake.

The insulin tolerance test has long been the reference standard for diagnosing growth hormone deficiency, but it is contraindicated in some patients, which created demand for a safer stimulus. A Japanese study evaluated the GH response to GHRP-2 in 56 children with growth disorders, using a 2 µg/kg intravenous dose (Asakura et al., Journal of Pediatric Endocrinology and Metabolism 2010;23(5):473–480, PMID 20662346).

Peak GH values correlated favourably with the insulin tolerance test (p<0.0001). Median peak GH was 3.39 µg/L in children with GH deficiency versus 25.10 µg/L in those without (p<0.0001), and the sensitivity-specificity crossover point fell at 15 µg/L. The test was safe and took an hour or less. The paper also notes that GHRP-2 had already been validated as a safe and reliable test for severe adult GH deficiency.

This is the strongest human evidence for GHRP-2 — and it is evidence that the peptide is a dependable pharmacological probe, not that dosing it repeatedly achieves anything.

The other well-documented human finding is one users often encounter without expecting it. Seven lean, healthy men received a subcutaneous infusion of GHRP-2 at 1 µg/kg/h or saline for 270 minutes, after which their intake at an ad libitum buffet meal was measured (Laferrère et al., JCEM 2005;90(2):611–614, PMID 15699539).

Participants ate 35.9 ± 10.9% more on GHRP-2 than on saline. Every single subject increased intake when calculated per kilogram of body weight (136.0 ± 13.0 kJ/kg versus 101.3 ± 10.5 kJ/kg, p=0.008), with no change in the macronutrient composition of what they chose. Serum GH rose sharply as expected (AUC 5,550 ± 1,090 versus 412 ± 161 µg/L per 240 min, p=0.003).

The mechanism is straightforward: GHRP-2 is a synthetic agonist at the growth hormone secretagogue receptor, the same receptor ghrelin binds, and ghrelin drives both GH release and meal initiation. The two effects are not separable at the receptor. With n=7 this is a small study, but the effect was uniform across subjects — worth knowing for anyone whose stated goal is losing fat.

The literature has a clear shape: acute endocrine pharmacology, thoroughly covered; chronic administration, essentially absent. There is no published randomised trial of repeated GHRP-2 dosing reporting lean mass, fat mass, strength, recovery, sleep quality, or injury healing. There is no long-term safety data, which matters because sustained secretagogue stimulation raises the same questions as any GH-axis intervention — insulin sensitivity, glucose tolerance, and the consequences of chronically elevated IGF-1.

Two further findings from the diagnostic literature are relevant. GHRP-2 also stimulates prolactin and cortisol release, which is why studies of pituitary-adrenal responsiveness use it, and intravenous GHRP-2 alters GH isoform profiles in a way that is documented in anti-doping research — the peptide is prohibited in sport by the World Anti-Doping Agency.

GHRP-2 has no FDA-approved therapeutic indication. Its recognised clinical role is diagnostic, at a single low intravenous dose, under supervision — a use case with almost nothing in common with repeated self-administration.

When a source cites "clinical validation" for GHRP-2, the accurate reading is that a single injection reliably produces a measurable GH spike. That is the validated claim. Extending it to sustained benefit from ongoing use requires trials that have not been run.